Tirzepatide brand name options include Mounjaro and Zepbound, both made by Eli Lilly. Learn what each is approved for and why no generic exists.
Tirzepatide is sold under two brand names in the United States: Mounjaro, approved for type 2 diabetes, and Zepbound, approved for chronic weight management and obstructive sleep apnea. Both products are made by Eli Lilly and contain the identical active ingredient. There is currently no FDA-approved generic tirzepatide sold in the US.
The Two Tirzepatide Brand Names Available in the US
Tirzepatide is a once-weekly injectable medication in a drug class called dual GIP and GLP-1 receptor agonists. Which name appears on the box depends on what the FDA approved that product to treat.
| Brand name | Manufacturer | FDA-approved uses | Available forms |
|---|---|---|---|
| Mounjaro | Eli Lilly | Type 2 diabetes (2022) | Single-dose pens, single-dose vials |
| Zepbound | Eli Lilly | Chronic weight management (2023); obstructive sleep apnea in adults with obesity (2024) | Single-dose pens, single-dose vials through LillyDirect |
Same molecule, same doses, same once-weekly schedule. Many people search for a tirzepatide generic name without realizing that "tirzepatide" is already the nonproprietary, or generic, name. Mounjaro and Zepbound are simply the branded versions of it.
Mounjaro vs Zepbound: What Actually Differs
Because the active drug is identical, the differences come down to labeling, insurance, and price rather than chemistry.
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Primary approved condition | Type 2 diabetes | Obesity or overweight with a related condition; sleep apnea |
| Starting dose | 2.5 mg weekly | 2.5 mg weekly |
| Maximum dose | 15 mg weekly | 15 mg weekly |
| Insurance coverage | Frequently covered for diabetes | Coverage varies widely by plan |
| Cash price | List price above $1,000 per month | List price above $1,000 per month; single-dose vials cost less |
Prices and savings programs change often, so confirm current numbers with the manufacturer or your pharmacy. A prescription written for one brand is not automatically filled as the other, even though the drug inside is the same.
Is There a Generic Tirzepatide Yet?
No. Tirzepatide is a synthetic peptide protected by patents held by Eli Lilly, and no generic version has received FDA approval. Peptides are far more complex to copy than ordinary chemical drugs, which makes a true generic a slow, expensive process rather than a simple application.
Compounded tirzepatide filled a gap during the 2022 to 2024 supply shortage. The FDA declared that shortage resolved in December 2024 and told compounding pharmacies to stop producing copies, so compounded tirzepatide is no longer broadly legal to sell.
Compounded and imported versions are not FDA-approved, are not verified for quality the same way brand products are, and have been tied to dosing errors. Anyone considering one should speak with a licensed healthcare professional first.
Other Names for Tirzepatide
- Tirzepatide — the international nonproprietary name, which is the generic name.
- LY3298176 — Eli Lilly's internal research code used during clinical trials.
- Mounjaro KwikPen — a multi-dose pen device sold in the UK and some other countries.
- GIP/GLP-1 dual agonist or "twincretin" — class descriptions, not brand names.
People tracking newer compounds sometimes search for a retatrutide brand name or compare cagrilintide vs tirzepatide, but those are separate molecules with their own development timelines and no US approval.
Doses and Forms of Tirzepatide
| Strength | Typical step | Purpose |
|---|---|---|
| 2.5 mg | Starting dose | First four weeks, not a maintenance dose |
| 5 mg | Step 2 | First maintenance dose |
| 7.5 mg | Step 3 | Titration |
| 10 mg | Step 4 | Titration |
| 12.5 mg | Step 5 | Titration |
| 15 mg | Maximum | Highest approved weekly dose |
Every strength is given as a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm. Prescribers increase the dose gradually to limit gastrointestinal side effects. There is no approved oral tirzepatide product in the US.
Safety, Side Effects, and Practical Considerations
Common side effects include nausea, vomiting, diarrhea, constipation, and reduced appetite. More serious risks include pancreatitis, gallbladder disease, and low blood sugar when tirzepatide is combined with insulin or sulfonylureas.
Tirzepatide carries a boxed warning about thyroid C-cell tumors observed in rodents. It should not be used by anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome.
People often ask can you take semaglutide and tirzepatide at the same time. Combining two GLP-1-based drugs is not an approved regimen and raises the risk of severe gastrointestinal side effects.
Some clinics market injections alongside other compounds. If you have seen advertising for lipo-c and tirzepatide, or read about tirzepatide with l-carnitine, know that those combinations are not FDA-approved and have limited human data behind them.
The Bottom Line
Tirzepatide has two brand names in the United States, Mounjaro and Zepbound, and Eli Lilly makes both. No generic version exists, and compounded copies are no longer widely permitted after the shortage ended.
Anyone considering tirzepatide should review their health history, medication list, and budget with a healthcare professional before starting treatment.
Frequently Asked Questions
What is the brand name for tirzepatide?
Tirzepatide is marketed under two brand names in the US: Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. Both are made by Eli Lilly and contain the same active ingredient at the same strengths.
Is there a generic version of tirzepatide available in the US?
No FDA-approved generic tirzepatide is sold in the United States. Because tirzepatide is a complex synthetic peptide, it is protected by patents and would require a biosimilar-style approval process rather than a standard generic application.
Are Mounjaro and Zepbound the same medication?
Yes. Mounjaro and Zepbound both contain tirzepatide and are dosed the same way, up to 15 mg once weekly by injection. The difference is the FDA-approved indication on the label, which affects insurance coverage and how the prescription is written.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.